Sign In

Grant Runyan

Director, Biostatistics at SDC (Statistics & Data Corporation)

Professional Background

Grant Runyan is a highly skilled statistician and biostatistics expert with over two decades of extensive experience in the pharmaceutical and biopharmaceutical industries. He currently serves as the Director of Biostatistics at SDC (Statistics & Data Corporation), where he has been instrumental since February 2020. SDC is renowned for providing strategic scientific consulting and clinical data services, including biostatistics, data management, and interactive response technology (IRT) to various pharmaceutical, biologic, and medical device companies. With a keen focus on the central nervous system (CNS) therapeutic area, Grant has contributed significantly to projects addressing critical health conditions such as Alzheimer’s Disease (AD), Parkinson's Disease (PD), Post-Traumatic Stress Disorder (PTSD), Lewy Body Dementia, schizophrenia, and pain related to Diabetic Peripheral Neuropathy (DPN) and fibromyalgia (FM).

Career Path

Prior to his current role, Grant demonstrated his adeptness in biostatistics through several high-impact positions. From September 2018 to November 2019, he was the Director of Biostatistics at Aptinyx Inc., a clinical-stage biopharmaceutical company dedicated to pioneering novel therapies for complex disorders of the brain and nervous system. In this capacity, Grant was responsible for ensuring the statistical integrity of outputs, overseeing biostatistics operations, and maintaining quality, data integrity, and overall efficiency in statistical processes.

Earlier in his career, from October 2017 to September 2018, Grant contributed his expertise as a statistician at Pentara Corporation, a notable contract research organization (CRO) specializing in the design and efficacy analysis of clinical studies related to Alzheimer’s Disease. His experience at Pentara further solidified his skill set in addressing neurological disorders and their treatment pathways.

Grant’s foundation in the field was laid at Takeda Pharmaceuticals, where he served as a Manager in Statistics starting in 2006. He successfully handled numerous oncology projects and played a pivotal role in leading an Analytical Science team that responded to regulatory inquiries regarding ACTOS (pioglitazone). Following the merger with TAP Pharmaceuticals, Grant transitioned into a technical role, participating in co-development projects with Affymax and Zinfandel Pharmaceuticals, focusing on treatments for anemia due to chronic renal failure and Mild Cognitive Impairment (MCI) related to Alzheimer's Disease.

Before his tenure at Takeda, Grant worked with Quintiles (now QuintilesIMS), where he held various positions as Randomization Team Lead, Manager, and later as Associate Director. His critical contributions included serving as the Lead Statistician for a series of global asthma studies, culminating in a successful U.S. FDA New Drug Application (NDA) submission. Additionally, Grant's early career began at Hoechst Marion Roussel, where he was a statistician involved in an anemia FDA Biologics License Application (BLA) submission program, orchestrating multiple Phase II and III studies.

Education and Achievements

Grant Runyan's educational background showcases his commitment to academic excellence and a solid foundation in statistics and engineering. He earned a Bachelor of Science degree in Chemical Engineering, complemented by additional majors in Statistics and Mathematics from Iowa State University. This diverse academic background equipped him with the analytical skills necessary to excel in his field.

Grant further advanced his education by obtaining a Doctor of Philosophy (PhD) in Statistics from the University of Minnesota-Twin Cities in 1998. His doctoral studies allowed him to deepen his knowledge and expertise in statistical methods, which have been indispensable assets throughout his career.

Throughout his career, Grant has received accolades for his innovative methodologies and contributions to significant clinical studies. His efforts have played a crucial role in advancing treatments for diseases that profoundly impact lives and have garnered recognition within the scientific community.

Notable Achievements

  1. Leadership in CNS Therapeutics: As a Director of Biostatistics, Grant has successfully led statistical operations on various clinical trials related to central nervous system diseases, demonstrating his capacity to handle complex datasets and contribute to meaningful therapeutic advancements.

  2. Pivotal Roles in Drug Development: His expertise in biostatistics has been vital in overseeing the statistical integrity of clinical programs, ensuring they meet regulatory standards and contribute successfully to the development of life-changing therapies.

  3. Successful FDA Submissions: Grant's statistical analyses have been critical in securing regulatory approvals for drugs, thus facilitating the launch of therapies that address unmet medical needs.

Grant Runyan
Add to my network

Location

Lake Villa, Illinois, United States